Intellipharmaceutics International Inc. (IPCI)

[fabius]

they are trading @ 25% below the offering price.

Market seems to be considering the company as almost dead due to total management failure. NASDAQ compliance seems to be difficult to obtain...they are now behaving like penny-land stocks/companies.


The reason the offering is covering the 12months burn rate is just for Nasdq compliance (the proven 1year sustainability).

I am surprised to still see Boyd around (even if he could already have sold off its shares; given the delay allowed for the SEC filing.)

From the Q3 notes it seems they are trying to push Oxy ahead on their own. Let's see which are the final data on HAP/HAL studies. If they are not above the competition the end is very close.